Darabioscienceincis A Clinical Stagebiopharmaceutical Company Focused On Advancing Innovativeproducts For Women S Healththecompany Aims To Address Unmet Needs In Areas Such As Contraceptionsexual Healthpelvic Painfertilityinfectious Diseasesvaginal Healthand Menopauseunder Theleadership Of President And Ceo Sabrina Martucci Johnsondarais Committed To Developing Evidencebased Treatment Solutions Thecompany Identifiesdevelopsand Markets Products Designed To Improvewomen S Healthits First Fda Approved Productxaciatoa Cclindamycin Phosphatevaginal Gel 2 Is Indicated For Thetreatment Of Bacterial Vaginosis In Femalepatients Aged 12 And Olderadditionallydarais Developing Ovaprenea Potential First In Category Candidatecurrently In Clinical Developmentdarabioscienceis Listed On Thenasdaq Under Theticker Symbol Dareand Actively Engages With Investors To Shareupdates On Its Progress And Financial Performance
